X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ovarest® (leuprolide) is a gonadotropin-releasing hormone analogue that is used to treat endometriosis and uterine fibroids in women, prostate cancer in men, and central precocious puberty in boys and girls.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovarest
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
The milestone payment is related to continued clinical progress of Oral KORSUVA (difelikefalin), which is currently the subject of four separate clinical programs for pruritus in patients with hepatic impairment due to primary biliary cholangitis.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: Korsuva
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: CARA Therapeutics
Deal Size: $46.0 million Upfront Cash: $8.0 million
Deal Type: Licensing Agreement October 10, 2022
Details:
Oral administration of Ovarest (leuprolide) offers the potential to better address diseases in which gonadotropin-releasing hormone (GnRH) agonists are known to provide benefit and for which an oral format can improve patient compliance.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovarest
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: SWK Holdings
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Details:
Enteris is eligible to receive additional potential milestone payments over the next several quarters, subject to the achievement of certain development milestones for Oral KORSUVA, of which Enteris will retain half.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: Korsuva
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: CARA Therapeutics
Deal Size: $25.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement December 09, 2021
Details:
This milestone payment was triggered by confirmation from Cara of the completion of an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) for Oral KORSUVA in patients with non-dialysis dependent (NDD) chronic kidney disease (CKD-aP).
Lead Product(s): Difelikefalin
Therapeutic Area: Nephrology Product Name: Korsuva
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: CARA Therapeutics
Deal Size: Undisclosed Upfront Cash: $8.0 million
Deal Type: Licensing Agreement June 11, 2021
Details:
Enteris BioPharma, received a second milestone payment from Cara Therapeutics (Nasdaq: CARA) related to the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA, the oral formulation of Cara’s first-in-class KOR agonist, CR845/difelikefalin.
Lead Product(s): Difelikefalin
Therapeutic Area: Dermatology Product Name: Korsuva
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: CARA Therapeutics
Deal Size: $13.0 million Upfront Cash: $8.0 million
Deal Type: Licensing Agreement December 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
